Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Finds Licensing More Palatable Than Large Acquisitions

This article was originally published in The Pink Sheet Daily

Executive Summary

During BIO-Europe panel, AstraZeneca exec says firm’s $15.6 billion acquisition of MedImmune gives it major inroads into biologics.

You may also be interested in...

Alnylam Signs Billion Dollar RNAi Deal With Roche

Best path to build value for shareholders is to maintain independent, focused and hungry biotech culture, Alnylam CEO tells “The Pink Sheet” DAILY.

The Value of Proof-Of-Concept

Big Pharma's unprecedented spending levels in licensing continue. But some recent deals suggest the real linchpin of licensing value is proof-of-concept in humans.

AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune

Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts